Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 2, 2014, Pages 431-440

  Jain, Sanyog ^a   Harde, Harshad ^a   Indulkar, Anura ^a   Agrawal, Ashish Kumar ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Bilosomes; Mannosylation; Oral immunization; Tetanus toxoid; Vaccine delivery

Indexed keywords

BILOSOMES; MANNOSYLATION; ORAL IMMUNIZATION; TETANUS TOXOID; VACCINE DELIVERY;

ADMINISTRATION, ORAL; ADSORPTION; ANIMALS; CELL LINE; DRUG CARRIERS; IMMUNITY, MUCOSAL; INTERFERON-GAMMA; INTERLEUKIN-2; LIPOSOMES; MACROPHAGES; MALE; MANNANS; MANNOSE; MICE; MICE, INBRED BALB C; MOUTH MUCOSA; NANOMEDICINE; PHOSPHATIDYLETHANOLAMINES; POLYMERS; PROTEIN CONFORMATION; SERUM ALBUMIN, BOVINE; SURFACE PROPERTIES; TETANUS TOXOID;

EID: 84895068018     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.08.012     Document Type: Article

References (37)

1. Jain S., Singh P., Mishra V., Vyas S.P. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B. Immunol Lett 2005, 101:41-49.
2. Jain S., Vyas S.P. Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J Liposome Res 2006, 16:331-345.
3. Rothkotter H.J., Pabst R., Bailey M. Lymphocyte migration in the intestinal mucosa: entry, transit and emigration of lymphoid cells and the influence of antigen. Vet Immunol Immunopathol 1999, 72:157-165.
4. Des Rieux A., Fievez V., Garinot M., Schneider Y.J., Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006, 116:1-27.
5. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
6. Giddam A.K., Zaman M., Skwarczynski M., Toth I. Liposome-based delivery system for vaccine candidates: constructing an effective formulation. Nanomedicine 2012, 7:1877-1893.
7. Uchegbu I.F., Vyas S.P. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998, 172:33-70.
8. van der Lubben I.M., Verhoef J.C., van Aelst A.C., Borchard G., Junginger H.E. Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials 2001, 22:687-694.
9. Borges O., Borchard G., Verhoef J.C., de Sousa A., Junginger H.E. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm 2005, 299:155-166.
10. Mann J.F., Scales H.E., Shakir E., Alexander J., Carter K.C., Mullen A.B., et al. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 2006, 38:90-95.
11. Myschik J., Rades T., Hook S. Advances in lipid-based subunit vaccine formulations. Curr Immunol Rev 2009, 5:42-48.
12. Romero E.L., Morilla M.J. Topical and mucosal liposomes for vaccine delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011, 3:356-375.
13. Singh P., Prabakaran D., Jain S., Mishra V., Jaganathan K.S., Vyas S.P. Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization. Int J Pharm 2004, 278:379-390.
14. Frey A., Giannasca K.T., Weltzin R., Giannasca P.J., Reggio H., Lencer W.I., et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med 1996, 184:1045-1059.
15. Jani P., Halbert G.W., Langridge J., Florence A.T. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989, 41:809-812.
16. Ahsan F., Rivas I.P., Khan M.A., Torres Suarez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 2002, 79:29-40.
17. Cuna M., Alonso-Sandel M., Remunan-Lopez C., Pivel J.P., Alonso-Lebrero J.L., Alonso M.J. Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. J Nanosci Nanotechnol 2006, 6:2887-2895.
18. Alonso-Sande M., Cuña M., Remuñán-López C., Teijeiro-Osorio D., Alonso-Lebrero J.L., Alonso M.J. Formation of new glucomannan-chitosan nanoparticles and study of their ability to associate and deliver proteins. Macromolecules 2006, 39:4152-4158.
19. Wang K., He Z. Alginate-konjac glucomannan-chitosan beads as controlled release matrix. Int J Pharm 2002, 244:117-126.
20. Du J., Sun R., Zhang S., Zhang L.F., Xiong C.D., Peng Y.X. Novel polyelectrolyte carboxymethyl konjac glucomannan-chitosan nanoparticles for drug delivery. I. Physicochemical characterization of the carboxymethyl konjac glucomannan-chitosan nanoparticles. Biopolymers 2005, 78:1-8.
21. Agrawal A.K., Das M., Jain S. In situ gel systems as' smart' carriers for sustained ocular drug delivery. Expert Opin Drug Deliv 2012, 9:383-402.
22. An N.T., Dong N.T., Dung P.L., Thien D.T. Synthesis and characterization of water-soluble O-carboxymethyl glucomannan derivatives. Carbohydr Polym 2011, 83:645-652.
23. Jain S., Rathi V.V., Jain A.K., Das M., Godugu C. Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. Nanomedicine (Lond) 2012, 7:1311-1337.
24. Sarti F., Perera G., Hintzen F., Kotti K., Karageorgiou V., Kammona O., et al. In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials 2011, 32:4052-4057.
25. Vila A., Sanchez A., Janes K., Behrens I., Kissel T., Vila Jato J.L., et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 2004, 57:123-131.
26. Zhu Y., Li X., Chen C., Wang F., Li J., Hu C., et al. Effects of aluminum trichloride on the trace elements and cytokines in the spleen of rats. Food Chem Toxicol 2012, 50:2911-2915.
27. Jain S., Kumar D., Swarnakar N.K., Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials 2012, 33:6758-6768.
28. Conacher M., Alexander J., Brewer J.M. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 2001, 19:2965-2974.
29. Agrawal A., Gupta P., Khanna A., Sharma R., Chandrabanshi H., Gupta N., et al. Development and characterization of in situ gel system for nasal insulin delivery. Pharmazie 2010, 65:188-193.
30. Jain S., Patil S.R., Swarnakar N.K., Agrawal A.K. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). Mol Pharmaceutics 2012, 9:2626-2635.
31. Choudhary H., Agrawal A., Malviya R., Yadav S., Jaliwala Y., Patil U. Evaluation and optimization of preparative variables for controlled-release floating microspheres of levodopa/carbidopa. Pharmazie 2010, 65:194-198.
32. Hopkins S., Niedergang F., Corthesy-Theulaz I., Kraehenbuhl J. A recombinant Salmonella typhimurium vaccine strain is taken up and survives within murine Peyer's patch dendritic cells. Cell Microbiol 2000, 2:59-68.
33. Furumoto K., Nagayama S., Ogawara K., Takakura Y., Hashida M., Higaki K., et al. Hepatic uptake of negatively charged particles in rats: possible involvement of serum proteins in recognition by scavenger receptor. J Control Release 2004, 97:133-141.
34. Jain S., Kumar S., Agrawal A.K., Thanki K., Banerjee U.C. Enhanced transfection efficiency and reduced cytotoxicity of novel lipid-polymer hybrid nanoplexes. Mol Pharmaceutics 2013, 10:2416-2425.
35. Tacken P.J., Figdor C.G. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol 2011, 23:12-20.
36. Mackay I.R., Rosen F.S., Ada G. Vaccines and vaccination. N Engl J Med 2001, 345:1042-1053.
37. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 2009, 103:161-179.